ALSO IN THIS MONTH'S ISSUE

• Most Favored Nation Pricing Temporarily Halted By Courts

  In late December, the courts halted President Trump’s international reference-pricing scheme, the Most Favored Nation model, saying the administration had improperly attempted to implement a radical change in Medicare reimbursement policy.

• Going Public In Mid-Pandemic

  Just as the COVID pandemic hit, Timber Pharma was planning on going public. But that wasn’t the only challenge the company faced in the months ahead.

• 5 Elements Of A Long-Term Partnership Strategy

  Throughout my career, I have seen partnerships that succeed and those that fail. Through this experience, I have been able to identify what it takes to build and maintain partnerships that stand the test of time.

• Benefits Of Beantown Biotech And Lessons For Life Science Leaders

  I have had the opportunity to experience and contribute to the thriving life sciences industry in Massachusetts, and I can say that it has all of the components needed to ultimately bring new treatments forward for patients.

• Increasing Patient Diversity In Clinical Trials

  The COVID-19 pandemic has spotlighted healthcare’s biggest shortfalls. One of the most glaring problems sounds like it should be simple to resolve, but it has actually been challenging to implement — diversity in clinical trials.